Nadine Housri, MD
Associate Professor AdjunctDownloadHi-Res Photo
Cards
Appointments
Therapeutic Radiology
Primary
Contact Info
About
Titles
Associate Professor Adjunct
Biography
Dr. Housri’s clinical focus is in thoracic oncology and stereotactic radiosurgery.
Appointments
Therapeutic Radiology
Associate Professor AdjunctPrimary
Other Departments & Organizations
Education & Training
- Fellow
- Yale School of Medicine (2015)
- Resident
- Rutgers Robert Wood Johnson Medical School (2014)
- MD
- University of Miami Miller School of Medicine (2009)
Research
Overview
Medical Research Interests
Lung
Research at a Glance
Yale Co-Authors
Frequent collaborators of Nadine Housri's published research.
Publications Timeline
A big-picture view of Nadine Housri's research output by year.
Christin A. Knowlton, MD, MA
Henry S. Park, MD, MPH
Thomas Hayman, MD, PhD
Christopher J. Tien, PhD, DABR, FAAPM
James B. Yu, MD, MHS, FASTRO
James Bond, PhD
44Publications
498Citations
Publications
2024
Complete vs. Incomplete Consolidative Radiotherapy in Patients with Extensive-Stage Small Cell Lung Cancer
Ninia J, Verma N, Laird J, Hayman T, Knowlton C, Peters G, Campbell A, Housri N, Feghali K, de Jong D, Park H. Complete vs. Incomplete Consolidative Radiotherapy in Patients with Extensive-Stage Small Cell Lung Cancer. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: e51. DOI: 10.1016/j.ijrobp.2024.07.1890.Peer-Reviewed Original ResearchConceptsExtensive-stage small cell lung cancerProgression-free survivalSmall cell lung cancerOverall survivalCell lung cancerOligometastatic diseaseChemo-immunotherapyLung cancerSuperior progression-free survivalMedian follow-up timePatients treated with CCSites of disease involvementConsolidative thoracic radiotherapyAssociated with improved outcomesChemotherapy-based treatmentStratified Cox proportional hazard regressionsLog-rank testCox proportional hazards regressionDisease burdenTime of diagnosisKaplan-Meier estimatesProportional hazards regressionConsolidation radiotherapyPolymetastatic diseaseOligometastatic patientsRadioresistant Pulmonary Oligometastatic and Oligoprogressive Lesions From Nonlung Primaries: Impact of Histology and Dose-Fractionation on Local Control After Radiation Therapy
Verma N, Laird J, Moore N, Hayman T, Housri N, Peters G, Knowlton C, Jairam V, Campbell A, Park H. Radioresistant Pulmonary Oligometastatic and Oligoprogressive Lesions From Nonlung Primaries: Impact of Histology and Dose-Fractionation on Local Control After Radiation Therapy. Advances In Radiation Oncology 2024, 9: 101500. PMID: 38699671, PMCID: PMC11063223, DOI: 10.1016/j.adro.2024.101500.Peer-Reviewed Original ResearchCitationsAltmetricConceptsLocal recurrence-free survivalNon-lung primaryAssociated with higher local recurrence-free survivalProgression-free survivalBiologically effective doseLocal controlRadioresistant metastasesOverall survivalPulmonary metastasesPrimary cancerColorectal carcinomaAssociated with superior local controlMultivariate analysisPatients treated with radiotherapyRisk of local recurrenceMedian follow-up timeMultivariable Cox proportional hazards regressionInferior local controlMedian total doseSuperior local controlAssociated with decreased riskImpact of histologyMetastasis-free survivalRecurrence-free survivalLocal failureDose-volume Predictors of Radiation Pneumonitis Following Thoracic Hypofractionated Radiotherapy
Sasse A, Oh P, Saeed N, Yang D, Hayman T, Knowlton C, Peters G, Campbell A, Laird J, Housri N, Park H. Dose-volume Predictors of Radiation Pneumonitis Following Thoracic Hypofractionated Radiotherapy. International Journal Of Radiation Oncology • Biology • Physics 2024, 118: e5. DOI: 10.1016/j.ijrobp.2023.10.054.Peer-Reviewed Original ResearchConceptsHypofractionated radiation therapyRisk of gradeUltra-central tumoursRadiation pneumonitisLung V20Lung V5Central tumorsMultivariable logistic regression analysisSingle health care systemDose-volume predictorsDosimetric risk factorsGrade 5 toxicitySimilar local controlDose-fractionation regimensProbability of gradeProximal tracheobronchial treeLogistic regression analysisMATERIAL/METHODSHealth care systemPrimary endpointOverall survivalHypofractionated radiotherapyMultivariable analysisLung doseThoracic tumorsDosimetric Factors Associated with Esophagitis Following Hypofractionated Radiotherapy to the Thorax
Sasse, Oh P, Saeed N, Yang D, Peters G, Hayman T, Housri N, Laird J, Campbell A, Knowlton C, Park H. Dosimetric Factors Associated with Esophagitis Following Hypofractionated Radiotherapy to the Thorax. International Journal Of Radiation Oncology • Biology • Physics 2024, 118: e7-e8. DOI: 10.1016/j.ijrobp.2023.10.059.Peer-Reviewed Original ResearchConceptsHypofractionated radiation therapyTotal patientsOverall survivalLocal controlUltra-central lung tumorsMultivariable logistic regression analysisSignificant differencesComparable local controlGrade 3 esophagitisRisk of gradeCases of gradeProbability of gradeLogistic regression analysisMATERIAL/METHODSMean esophagus doseSingle healthcare systemEsophagus DmaxPrimary endpointHypofractionated radiotherapyDosimetric factorsMultivariable analysisEsophagus doseThoracic tumorsDosimetric variablesClinical trials
2023
Dose-Volume Predictors of Radiation Pneumonitis After Thoracic Hypofractionated Radiation Therapy
Sasse A, Oh P, Saeed N, Yang D, Hayman T, Knowlton C, Peters G, Campbell A, Laird J, Housri N, Park H. Dose-Volume Predictors of Radiation Pneumonitis After Thoracic Hypofractionated Radiation Therapy. Practical Radiation Oncology 2023, 14: e97-e104. PMID: 37984711, DOI: 10.1016/j.prro.2023.11.006.Peer-Reviewed Original ResearchCitationsAltmetricConceptsMean lung doseHypofractionated radiation therapyRisk of gradeRadiation pneumonitisLung V20Lung V5Dose-volume predictorsDosimetric risk factorsLogistic regression analysisGrade 5 casesSingle healthcare systemPrimary endpointDose regimensMultivariable analysisLung doseThoracic tumorsDosimetric variablesRisk factorsPneumonitisRadiation therapyCommon treatmentClinical practicePatientsSignificant associationPotential predictorsResponse time of high impact factor medical journals versus an expert-curated, online oncology platform before and during the COVID-19 pandemic.
Lubas M, Lukez A, Henry E, Housri N, Egleston B, Howell K. Response time of high impact factor medical journals versus an expert-curated, online oncology platform before and during the COVID-19 pandemic. JCO Oncology Practice 2023, 19: 465-465. DOI: 10.1200/op.2023.19.11_suppl.465.Peer-Reviewed Original ResearchDose-Escalated vs. Conventional Hypofractionated Radiotherapy for Lung Cancer Patients in Predominantly Central Locations
Sasse A, Saeed N, Oh P, Housri N, Knowlton C, Hayman T, Peters G, Campbell A, Yang D, Park H. Dose-Escalated vs. Conventional Hypofractionated Radiotherapy for Lung Cancer Patients in Predominantly Central Locations. International Journal Of Radiation Oncology • Biology • Physics 2023, 117: e55. DOI: 10.1016/j.ijrobp.2023.06.768.Peer-Reviewed Original ResearchConceptsStereotactic body radiotherapyUltra-central tumoursHypofractionated radiation therapyHigh local controlOverall survivalGrade 3Local controlLung cancerNon-small cell lung cancerPromising local controlOutcomes of patientsEffective treatment regimenCell lung cancerHigher overall survivalLung cancer patientsMATERIAL/METHODSMedian ageHypofractionated radiotherapyTreatment regimenBody radiotherapyBaseline variablesCancer patientsTreatment optionsTumor locationChi-square analysisSurvival Outcomes for Oligometastatic vs. Polymetastatic Extensive-Stage Small Cell Lung Cancer Following Consolidative Thoracic Radiotherapy
Verma N, Ninia J, Hayman T, Housri N, Peters G, Knowlton C, Campbell A, Park H. Survival Outcomes for Oligometastatic vs. Polymetastatic Extensive-Stage Small Cell Lung Cancer Following Consolidative Thoracic Radiotherapy. International Journal Of Radiation Oncology • Biology • Physics 2023, 117: e68-e69. DOI: 10.1016/j.ijrobp.2023.06.797.Peer-Reviewed Original ResearchConceptsLocal recurrence-free survivalProgression-free survivalES-SCLC patientsES-SCLCOligometastatic diseaseOligometastatic patientsImproved OSLung involvementExtensive-stage small-cell lung cancerMultivariable Cox proportional hazards regressionMultivariable Cox regression analysisCox proportional hazards regressionSmall cell lung cancerBilateral lung involvementConsolidative thoracic radiotherapyLimited metastatic burdenMetastasis-directed radiotherapyPlatinum-doublet chemotherapyCox regression analysisMetastasis-free survivalRecurrence-free survivalTime of diagnosisProportional hazards regressionCell lung cancerLog-rank testLaunching the Mednet in Pulmonary Medicine: An Online Platform for Expert Answers to Real World Clinical Questions
Khan A, Housri N, Briones M. Launching the Mednet in Pulmonary Medicine: An Online Platform for Expert Answers to Real World Clinical Questions. 2023, a4286-a4286. DOI: 10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a4286.Peer-Reviewed Original Research
2022
Closing the Gap: Implementation of a Novel Interactive Virtual Tumor Board to Improve Expert Knowledge Sharing in Malignant Hematology
Ciuro J, Henry E, Housri N, Banerjee R, Brem E, Brooks T, Derman B, Hill B, Hofmeister C, Lunning M, Matasar M, Phillips T, Rutherford S, Zanwar S, Lee L. Closing the Gap: Implementation of a Novel Interactive Virtual Tumor Board to Improve Expert Knowledge Sharing in Malignant Hematology. Blood 2022, 140: 13180-13181. DOI: 10.1182/blood-2022-167959.Peer-Reviewed Original Research
News
News
- June 06, 2023
Dr. Nadine Housri receives Healio Disruptive Innovator Award
- June 23, 2022
Smilow Cancer Hospital Care Centers at Trumbull and Fairfield
- May 28, 2021
Yale Research to be Presented at 2021 ASCO Annual Meeting
- February 12, 2019Source: Inc.
Where Doctors Discuss the Toughest Questions--Privately